Looks Good-ONCY SITC 2023 Poster in metastatic breast cancerNovember 04, 2023 - Analysis of the HR+/HER2- breast cancer tumor microenvironment (TME) following immune priming with pelareorep and atezolizumab using imaging mass cytometry - Results from the AWARE-1 trial
Pelareorep primes the TME in advance of atezolizumab administration resulting in a decline of PDL1 tumor cells after addition of Tecentriq.
The increase of PDL1 expression on day 3 and the following decrease on day 21 as seen by IHC can likely be attributed to the reduction of PDL1 positive tumor cells as a result of treatment.
https://oncolyticsbiotech.com/wp-content/uploads/2023/11/SITC_Poster_FINAL.pdf
https://www.biospace.com/article/releases/oncolytics-biotech-and-solti-present-further-positive-pelareorep-translational-data-at-sitc/